Hepatocellular Carcinoma Clinical Trial
Official title:
A Phase I/II Study of Sorafenib With Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma
The purpose of this phase I study is to determine the maximal tolerable dose (MTD) of
thalidomide (THADO®) in combination with fixed dose of sorafenib (NEXAVAR®) for the
treatment of advanced or metastatic HCC.
The Phase II purpose of this study is to determine the disease control rate (complete
response + partial response + stable disease) for at least 4 months of sorafenib (NEXAVAR®)
plus phase I determined MTD of thalidomide (THADO®) in patients with advanced or metastatic
HCC.
This is a non-randomized, open-labeled, single-arm, multi-center, phase I /II clinical
study. The Phase I purpose of this study is to determine the maximal tolerable dose (MTD) of
thalidomide (THADO®) in combination with fixed dose of sorafenib (NEXAVAR®) for the
treatment of advanced or metastatic HCC, and the dose-limiting toxicity (DLT) profiles and
other toxicity profiles in patients receiving fixed dose of sorafenib (NEXAVAR®) plus
escalating dose of thalidomide (THADO). The Phase II primary objective of this study is to
determine the disease control rate (complete response + partial response + stable disease)
for at least 4 months of sorafenib (NEXAVAR®) plus phase I determined MTD of thalidomide
(THADO®) in patients with advanced or metastatic HCC. The Phase II secondary objective of
this study is to determine the objective tumor response rate, the time to tumor progression,
the progression-free survival, the overall survival, and the safety and adverse event
profiles, the changes of circulating biomarkers relating to angiogenesis and their
correlation with disease control rate.
The sample size are required up to 24 patients for the phase I study and 53 patients for the
phase II study.
Sorafenib (NEXAVAR®): supplied to Good Manufacturing Practice standards by Bayer Health
Care, Taiwan as a film-coated tablet, each of which contains sorafenib tosylate (274mg)
equivalent to 200 mg of sorafenib. Thalidomide (THADO®): supplied to Good Manufacturing
Practice standards by TTY Biopharm Co., Ltd. as a white-yellow capsule, each of which
contains 50 mg of thalidomide.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
| Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
| Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
| Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
| Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
| Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
| Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
| Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
| Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
| Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
| Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |